RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
GAY F
Collezione AOU Città della Salute di Torino
Items : 123
Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies. in Annals of hematology / Ann Hematol. 2025 Mar 31. doi: 10.1007/s00277-025-06333-x.
2025
AOU Città della Salute di Torino
Costa LJ; Gay F; Landgren O; Mateos MV; Moreau P; Touzeau C; Ertel F; McFadden I; Najdi R; Weisel K;
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies. in Annals of hematology / Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-024-06143-7.
2025
AOU Città della Salute di Torino
Costa LJ; Gay F; Landgren O; Mateos MV; Moreau P; Touzeau C; Ertel F; McFadden I; Najdi R; Weisel K;
Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma. in Hypertension research : official journal of the Japanese Society of Hypertension / Hypertens Res. 2025 Jan 22. doi: 10.1038/s41440-024-02084-w.
2025
ASL Città di Torino
AOU Città della Salute di Torino
Veglio F; Gay F; Bringhen S; Rabbia F; Leone D; Paladino A; Cesareo M; Colomba A; Votta S; Catarinella C; Mingrone G; Astarita A; Airale L; Fanelli E; Picca G; Milan A; Vallelonga F;
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor. in Bone marrow transplantation / Bone Marrow Transplant. 2025 Jan;60(1):79-82. doi: 10.1038/s41409-024-02432-x. Epub 2024 Oct 4.
2025
AOU Città della Salute di Torino
Bringhen S; Santoro A; Bruno B; Lorenzi M; Francisci T; Benevolo G; De Philippis C; Mannina D; Larocca A; Taurino D; Oliva S; D'agostino M; Mariotti J; Mercadante S; Gay F; Sarina B; Casson A; Garibaldi B; Bertuglia G; Mina R; Bramanti S;
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2025 Feb 18:JCO2401253. doi: 10.1200/JCO-24-01253.
2025
AOU Città della Salute di Torino
Kaiser MF; Sonneveld P; Cairns DA; Raab MS; San-Miguel Izquierdo J; Zhang R; Acosta J; Larocca A; Popat R; Li C; Baertsch MA; Brown SR; Lahuerta Palacios J; Gandhi AK; Macé S; Musto P; Yong K; Mai EK; Dubin F; Blade J; Capra A; Cook G; Bertsch U; Mateos MV; Boccadoro M; Jackson GH; Gutiérrez NC; Gay F; Weinhold N; et alii...
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2025 Apr;36(4):361-374. doi: 10.1016/j.annonc.2025.01.022. Epub 2025 Feb 7.
2025
AOU Città della Salute di Torino
Musto P; Engelhardt M; van de Donk NWCJ; Gay F; Terpos E; Einsele H; Fernández de Larrea C; Sgherza N; Bolli N; Katodritou E; Gentile M; Royer B; Derudas D; Jelinek T; Zamagni E; Rosiñol L; Paiva B; Caers J; Kaiser M; Beksac M; Hájek R; Spencer A; Ludwig H; Cavo M; Bladé J; Moreau P; Mateos MV; San-Miguel JF; Dimopoulos MA; et alii...
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review. in Frontiers in oncology / Front Oncol. 2025 Mar 12;15:1550644. doi: 10.3389/fonc.2025.1550644. eCollection 2025.
2025
AOU Città della Salute di Torino
Gay F; Zamagni E; Cole CE; Scheid C; Hultcrantz M; Chorazy J; Iheanacho I; Pandey A; Bitetti J; Boytsov N; Purser M; McNamara S; Iida S;
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. in Cancers / Cancers (Basel). 2024 Sep 4;16(17):3081. doi: 10.3390/cancers16173081.
2024
AOU Città della Salute di Torino
Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;
Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers 2024, 16, 3081. in Cancers / Cancers (Basel). 2024 Nov 21;16(23):3891. doi: 10.3390/cancers16233891.
2024
AOU Città della Salute di Torino
Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3.
2024
AOU Città della Salute di Torino
Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; et alii...
An IL-1?-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma. in Nature immunology / Nat Immunol. 2024 May;25(5):820-833. doi: 10.1038/s41590-024-01808-x. Epub 2024 Apr 10.
2024
AOU Città della Salute di Torino
van Duin M; Bruns H; Büttner-Herold M; Moreau P; Gay F; van de Woestijne PC; Sanders MA; Tahri S; van Beek G; Hoogenboezem RM; van Heusden T; Vermeulen M; Czeti Á; Appelman MK; Papazian N; Fokkema C; de Jong MME; Broijl A; Sonneveld P; Cupedo T;
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. in Blood cancer journal / Blood Cancer J. 2024 Jun 7;14(1):94. doi: 10.1038/s41408-024-01075-x.
2024
AOU Alessandria
AOU Città della Salute di Torino
Bruno B; Zamagni E; Stefanoni P; Palmieri S; Liberati AM; Monaco F; Annibali O; Galieni P; Garzia M; Olivero M; Rogers J; Ruggeri M; Pescosta N; Pisani F; Tosi P; Pascarella A; Pietrantuono G; Arigoni M; De Sabbata G; Bertamini L; Belotti A; Rota-Scalabrini D; D'Agostino M; Calogero RA; Boccadoro M; Musto P; Gay F;
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting / Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520. doi: 10.1200/EDBK_433520.
2024
AOU Città della Salute di Torino
Rees MJ; D'Agostino M; Leypoldt LB; Kumar S; Weisel KC; Gay F;
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. in Haematologica / Haematologica. 2024 Jul 1;109(7):2337-2340. doi: 10.3324/haematol.2023.284694.
2024
AOU Città della Salute di Torino
Mateos MV; Weisel K; Terpos E; Delimpasi S; Kastritis E; Zamagni E; Delforge M; Ocio E; Katodritou E; Gay F; Larocca A; Leleu X; Otero PR; Schjesvold F; Cavo M; Dimopoulos MA;
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2024
AOU Città della Salute di Torino
Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. in Blood / Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.
2024
AOU Città della Salute di Torino
Paris L; Zambello R; Mancuso K; Gamberi B; Palmas AD; Gozzetti A; Cellini C; Ballanti S; Velluti C; Vincelli ID; Ronconi S; Pavone V; Grasso M; Ledda A; Oliva S; Corradini P; Morè S; Belotti A; Rota-Scalabrini D; Bertuglia G; D'Agostino M; Petrucci MT; Bruno B; Musto P; Gay F;
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. in PloS one / PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024.
2024
AOU Città della Salute di Torino
Mollee P; McCaughan G; Gay F; Cook G; Augustson B; Huynh K; Waters N; Wellard C; Moore E; Wood EM; Fanning L; Harris A; Petrie D; Irving A; Spencer A; McQuilten ZK;
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
2024
AOU Città della Salute di Torino
Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...
Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. in Future oncology (London, England) / Future Oncol. 2023 Oct;19(31):2103-2121. doi: 10.2217/fon-2023-0021. Epub 2023 Sep 14.
2023
AOU Città della Salute di Torino
Haefliger B; Valluri S; Erler-Yates N; Ribbands A; Luke E; Lambert A; Bailey A; Martínez-Lopez J; Gay F;
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.
2023
AOU Città della Salute di Torino
Benjamin R; Hájek R; Zweegman S; Silkjaer T; Caers J; Mancuso K; Tacchetti P; Razawy W; Grasso M; Giaccone L; Offidani M; Lund T; van der Velden VHJ; Pour L; Gadisseur A; Pietrantuono G; Broijl A; Roeloffzen WWH; Wu KL; Schjesvold F; van der Holt B; Minnema MC; van de Donk NWCJ; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P;
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. in The Lancet. Oncology / Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6.
2023
AOU Città della Salute di Torino
Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P; et alii...
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
2023
AOU Città della Salute di Torino
Terpos E; Musto P; Engelhardt M; Delforge M; Cook G; Gay F; van de Donk NWCJ; Ntanasis-Stathopoulos I; Vangsted AJ; Driessen C; Schjesvold F; Cerchione C; Zweegman S; Hajek R; Moreau P; Einsele H; San-Miguel J; Boccadoro M; Dimopoulos MA; Sonneveld P; Ludwig H;
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.
2023
AOU Città della Salute di Torino
Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.
2023
AOU Città della Salute di Torino
Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.
2023
AOU Città della Salute di Torino
Grasso M; Zamagni E; Fioritoni F; Ballanti S; Cea M; Pescosta N; Pavone V; Ronconi S; Vincelli ID; Oddolo D; Capra A; Bertamini L; Cellini C; Gozzetti A; De Rosa L; Giuliani N; Aquino S; de Fabritiis P; Gamberi B; Palmas A; Rota-Scalabrini D; Paris L; Musto P; Mina R; Belotti A; Boccadoro M; Gay F;
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study. in Cancers / Cancers (Basel). 2023 Feb 2;15(3):955. doi: 10.3390/cancers15030955.
2023
AOU Città della Salute di Torino
Astarita A; Mingrone G; Airale L; Cesareo M; Colomba A; Catarinella C; Leone D; Gay F; Bringhen S; Veglio F; Milan A; Vallelonga F;
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. in Cancers / Cancers (Basel). 2023 Feb 10;15(4):1149. doi: 10.3390/cancers15041149.
2023
AOU Città della Salute di Torino
Mingrone G; Astarita A; Colomba A; Catarinella C; Cesareo M; Airale L; Paladino A; Leone D; Vallelonga F; Bringhen S; Gay F; Veglio F; Milan A;
A rational approach to functional high-risk myeloma. in Hematology. American Society of Hematology. Education Program / Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):433-442. doi: 10.1182/hematology.20230004
2023
AOU Città della Salute di Torino
Gay F; Bertuglia G; Mina R;
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. in Experimental hematology & oncology / Exp Hematol Oncol. 2023 Aug 10;12(1):71. doi: 10.1186/s40164-023-00434-x.
2023
AOU Città della Salute di Torino
Bandini C; Mereu E; Paradzik T; Labrador M; Maccagno M; Cumerlato M; Oreglia F; Prever L; Manicardi V; Taiana E; Ronchetti D; D'Agostino M; Gay F; Larocca A; Besse L; Merlo GR; Hirsch E; Ciarrocchi A; Inghirami G; Neri A; Piva R;
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. in Blood cancer journal / Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7.
2023
AOU Città della Salute di Torino
Raje N; Anderson K; Einsele H; Efebera Y; Gay F; Hammond SP; Lesokhin AM; Lonial S; Ludwig H; Moreau P; Patel K; Ramasamy K; Mateos MV;
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.
2022
AOU Alessandria
AOU Città della Salute di Torino
Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3132-3150. doi: 10.1200/JCO.21.01217. Epub 2022 Mar 31.
2022
AOU Città della Salute di Torino
Moreau P; Musto P; Munshi NC; Avet-Loiseau H; Gay F; Broijl A; Vermeulen M; Valent ET; Beverloo HB; van der Holt B; Hoogenboezem R; van der Velden VHJ; Cupedo T; van Duin M; Kuiper R; Hofste Op Bruinink D; Zweegman S; van de Donk NWCJ; Sonneveld P;
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
2022
AOU Città della Salute di Torino
Cook G; Larocca A; Hernández Rivas JM; Goldschmidt H; Kaiser MF; Cavo M; Zweegman S; Gay F; Dürig J; Mai EK; Capra A; Castellani G; Bonello F; van der Holt B; Salwender H; Bladé Creixenti J; Rocchi S; van de Donk NWCJ; Jackson G; Dall'Olio D; Mateos MV; Zamagni E; Waage A; Bertsch U; Lahuerta JJ; Wester R; Cairns DA; D'Agostino M; San-Miguel JF; et alii...
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. in Transplantation and cellular therapy / Transplant Cell Ther. 2022 Jun;28(6):284-293. doi: 10.1016/j.jtct.2022.03.019. Epub 2022 Mar 17.
2022
AOU Città della Salute di Torino
Silberman R; Iftikhar R; Abonour R; Moreau P; Otero PR; Malhotra P; Biran N; Callander N; Janakiram M; Mohty M; Prince M; Beksac M; Chaudhry M; Aljurf M; Costa L; Hou J; Schriber J; Quach H; Einsele H; Cook G; Gay F; Costello C; Poudyal BS; Cowan A; Garfall A; Lonial S; Kumar A; Shah N; Kansagra A; et alii...
The EHA Research Roadmap: Malignant Lymphoid Diseases. in HemaSphere / Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun.
2022
AOU Città della Salute di Torino
Dreyling M; André M; Gökbuget N; Tilly H; Jerkeman M; Gribben J; Ferreri A; Morel P; Stilgenbauer S; Fox C; Maria Ribera J; Zweegman S; Aurer I; Bödör C; Burkhardt B; Buske C; Dollores Caballero M; Campo E; Chapuy B; Davies A; de Leval L; Doorduijn J; Federico M; Gaulard P; Gay F; Ghia P; Grønbæk K; Goldschmidt H; Kersten MJ; et alii...
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma? in International journal of molecular sciences / Int J Mol Sci. 2022 Dec 14;23(24):15879. doi: 10.3390/ijms232415879.
2022
AOU Città della Salute di Torino
Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M;
Melflufen for the treatment of multiple myeloma. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2022 Apr;15(4):371-382. doi: 10.1080/17512433.2022.2075847. Epub 2022 Jun
2022
AOU Città della Salute di Torino
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV;
Multiple myeloma with t(11;14): unique biology and evolving landscape. in American journal of cancer research / Am J Cancer Res. 2022 Jul 15;12(7):2950-2965. eCollection 2022.
2022
AOU Città della Salute di Torino
Costa LJ; Dogan A; Hungria VT; Gay F; Fonseca R; Kumar SK; Bal S;
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. in Cancer / Cancer. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647. Epub 2021 Jun 28.
2021
AOU Città della Salute di Torino
Einsele H; Palumbo A; Straka C; Corradini P; Wäsch R; Gentili S; Schub N; Spada S; Pönisch W; Aquino S; Patriarca F; Montefusco V; Salvini M; Engelhardt M; Offidani M; Günther A; Gay F; Boccadoro M; Sonneveld P; Gramatzki M;
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 Oct 1;27(19):5195-5212. doi: 10.1158/1078-0432.CCR-21-1059.
2021
AOU Città della Salute di Torino
Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; et alii...
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. in Transplantation and cellular therapy / Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.
2021
AOU Città della Salute di Torino
Paiva B; Dwyer MO; Merz M; Melenhorst JJ; Maus MV; Kaiser M; Hillengass J; Gormley N; Ghobrial IM; Gay F; Foureau D; Brownstein C; Demolis P; Bhutani M; Bolli N; Bergsagel PL; Bahlis N; Holstein SA; Pasquini MC; Shah N; Wong SW; Usmani SZ; McCarthy PL;
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.
2021
AOU Città della Salute di Torino
Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; et alii...
The role of autologous stem-cell transplantation in multiple myeloma in 2021. in Current opinion in oncology / Curr Opin Oncol. 2021 Nov 1;33(6):642-647. doi: 10.1097/CCO.0000000000000783.
2021
AOU Città della Salute di Torino
Mina R; Gay F;
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. in Haematologica / Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.
2021
AOU Città della Salute di Torino
Engelhardt M; Musto P; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS;
Antibody-drug conjugates: when chemotherapy meets immuno-oncology. in The Lancet. Haematology / Lancet Haematol. 2021 Nov;8(11):e778-e779. doi: 10.1016/S2352-3026(21)00236-2. Epub 2021 Sep 13.
2021
AOU Città della Salute di Torino
Mina R; Gay F;
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino
Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...
When and How to Treat Relapsed Multiple Myeloma. in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting / Am Soc Clin Oncol Educ Book. 2021 Mar;41:358-375. doi: 10.1200/EDBK_320129.
2021
AOU Città della Salute di Torino
Nathwani N; Bertamini L; Banerjee R; Gay F; Shah N; Krishnan A;
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. in Blood cancer journal / Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0.
2021
AOU Città della Salute di Torino
Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P;
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. in Leukemia / Leukemia. 2021 Jun;35(6):1732-1744. doi: 10.1038/s41375-020-01049-5. Epub 2020 Oct 16.
2021
AOU Città della Salute di Torino
Szabo Z; Desgraz R; Cook G; Delforge M; Gay F; Mateos MV; Weisel K; DeCosta L; Moreau P;
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.
2021
AOU Città della Salute di Torino
Hájek R; Spencer A; Nagler A; Gaidano G; Belotti A; Benevolo G; Patriarca F; Mina R; Ruggeri M; Cascavilla N; de Fabritiis P; Mannina D; Liberati AM; Romano A; Capra A; Corradini P; Offidani M; Petrucci MT; Bertamini L; Zaccaria GM; Sonneveld P; Musto P; Boccadoro M; Gay F;
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2021 Jan;35(1):31-44. doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19.
2021
AOU Città della Salute di Torino
van de Donk N; Leleu X; Engelhardt M; Garderet L; Jackson G; Weisel K; Caers J; Delforge M; Mateos MV; Einsele H; Mohty M; Zojer N; Terpos E; Avet-Loiseau H; Gay F; Dimopoulos MA; Hajek R; Facon T; Driessen C; Zweegman S; Pawlyn C; San-Miguel J; Cavo M; Moreau P; Boccadoro M; Ludwig H; Goldschmidt H; Beksac M; Nijhof I; et alii...
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e21-e24. doi: 10.1016/j.clml.2020.08.019. Epub 2020 Sep 1
2021
AOU Città della Salute di Torino
Zamagni E; Boccadoro M; Gay F; Bonello F; Mina R;
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
2021
AO Cuneo
AOU Città della Salute di Torino
Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
2021
AOU Città della Salute di Torino
Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. in Haematologica / Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402.
2021
AOU Città della Salute di Torino
Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M;
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. in British journal of haematology / Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16.
2021
AOU Città della Salute di Torino
Sezer O; Sonneveld P; Reece D; Rasche L; Moreau P; Mohty M; Merlini G; Lentzsch S; Mateos MV; Leleu X; Leal da Costa F; Kyle RA; Kröger N; Jurczyszyn A; Hungria V; Hájek R; Gay F; Gahrton G; Fernández de Larrea C; Engelhardt M; Dispenzieri A; Einsele H; Dimopoulos MA; Cavo M; Caers J; Badros A; Anderson KC; Van de Donk NWCJ; Zamagni E; et alii...
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? in Leukemia research / Leuk Res. 2021 Aug;107:106592. doi: 10.1016/j.leukres.2021.106592. Epub 2021 Apr 24.
2021
AOU Città della Salute di Torino
Boccadoro M; Gay F; Oliva S; Bonello F; Ferrero D;
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. in Cancers / Cancers (Basel). 2021 Apr 1;13(7):1631. doi: 10.3390/cancers13071631.
2021
AOU Città della Salute di Torino
Astarita A; Mingrone G; Airale L; Vallelonga F; Covella M; Catarinella C; Cesareo M; Bruno G; Leone D; Giordana C; Cetani G; Salvini M; Gay F; Bringhen S; Rabbia F; Veglio F; Milan A;
MRD Assessment in Multiple Myeloma: Progress and Challenges. in Current hematologic malignancy reports / Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5.
2021
AOU Città della Salute di Torino
Bertamini L; D'Agostino M; Gay F;
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. in Frontiers in cardiovascular medicine / Front Cardiovasc Med. 2021 Apr 21;8:645678. doi: 10.3389/fcvm.2021.645678. eCollection 2021.
2021
AOU Città della Salute di Torino
Veglio F; Bringhen S; Gay F; Cetani G; Salvini M; Catarinella C; Avenatti E; Leone D; Bruno G; Crea T; Cesareo M; Maffei I; Airale L; Astarita A; Mingrone G; Vallelonga F; Milan A;
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. in Journal of clinical medicine / J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120.
2020
AOU Città della Salute di Torino
Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG;
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Sep 15;26(18):4832-4841. doi: 10.1158/1078-0432.CCR-20-0951. Epub 2020 Jul 2.
2020
AOU Città della Salute di Torino
D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; Gambella M; Bringhen S; Larocca A; Boccadoro M; Bolli N; Maura F; Gay F; D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; et alii...
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020
2020
AOU Città della Salute di Torino
Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ; Hillengass J; Korde N; Li Z; Mailankody S; Neri P; Parekh S; Pasquini MC; Puig N; Roodman GD; Samur MK; Shah N; Shah UA; Shi Q; Spencer A; Suman VJ; Usmani SZ; McCarthy PL; Holstein SA; Howard A; et alii...
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e355-e357. doi: 10.1016/S2352-3026(19)30254-6. Epub 2020 Mar 11.
2020
AOU Città della Salute di Torino
Gay F; Mina R; D'Agostino M;
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions. in Annals of translational medicine / Ann Transl Med. 2020 Jun;8(12):777. doi: 10.21037/atm.2020.02.65.
2020
AOU Città della Salute di Torino
Bertamini L; Gay F;
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
2020
AOU Città della Salute di Torino
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. in Haematologica / Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20.
2020
AOU Città della Salute di Torino
AOU Novara
Corradini P; Cavo M; Offidani M; Liberati AM; Sonneveld P; Hajek R; Nagler A; Ben-Yehuda D; Cascavilla N; Nozzoli C; Ballanti S; Galieni P; Patriarca F; Musto P; Musolino C; Ribolla R; De Paoli L; Di Raimondo F; Spada S; Boccadoro M; Gay F; Montefusco V;
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. in Blood / Blood. 2020 Dec 24;136(26):3033-3040. doi: 10.1182/blood.2020008150.
2020
AOU Città della Salute di Torino
Chari A; Samur MK; Martinez-Lopez J; Cook G; Biran N; Yong K; Hungria V; Engelhardt M; Gay F; García Feria A; Oliva S; Oostvogels R; Gozzetti A; Rosenbaum C; Kumar S; Stadtmauer EA; Einsele H; Beksac M; Weisel K; Anderson KC; Mateos MV; Moreau P; San-Miguel J; Munshi NC; Avet-Loiseau H;
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2020 Aug;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z. Epub 2020 May 22.
2020
AOU Città della Salute di Torino
Terpos E; Engelhardt M; Cook G; Gay F; Mateos MV; Ntanasis-Stathopoulos I; van de Donk NWCJ; Avet-Loiseau H; Hajek R; Vangsted AJ; Ludwig H; Zweegman S; Moreau P; Einsele H; Boccadoro M; San Miguel J; Dimopoulos MA; Sonneveld P; Terpos E; Engelhardt M; Cook G; Gay F; Mateos MV; Ntanasis-Stathopoulos I; van de Donk NWCJ; Avet-Loiseau H; Hajek R; Vangsted AJ; Ludwig H; et alii...
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. in Blood cancer journal / Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.
2020
AOU Città della Salute di Torino
Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omedé P; Boise LH; Roussou M; Giuliani N; Oliva S; Offidani M; Belotti A; Jaye DL; De Paoli L; Terpos E; Lonial S; Boccadoro M; Nooka AK; Dimopoulos MA;
Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. in Acta haematologica / Acta Haematol. 2020;143(5):481-485. doi: 10.1159/000502538. Epub 2019 Sep 25.
2020
AOU Città della Salute di Torino
Fizzotti M; Aglietta M; Becco P; Bonzano A; Lombardi P; Marandino L; Ghisoni E; Gay F; Rota Scalabrini D;
Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. in Frontiers in oncology / Front Oncol. 2020 Oct 6;10:607571. doi: 10.3389/fonc.2020.607571. eCollection 2020.
2020
AOU Città della Salute di Torino
Gay F; Kastritis E; van de Donk NWCJ;
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. in Cancers / Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735.
2019
AOU Città della Salute di Torino
Bonello F; Pulini S; Ballanti S; Gentile M; Spada S; Annibali O; Omedé P; Ronconi S; Cangialosi C; Podda L; Palmas A; Malfitano A; Rivoli G; Belotti A; Ciambelli F; Vincelli ID; Cafro AM; Innao V; Palumbo A; Sonneveld P; Spencer A; Hájek R; Boccadoro M; Gay F;
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. in Cancers / Cancers (Basel). 2019 May 3;11(5):622. doi: 10.3390/cancers11050622.
2019
AOU Città della Salute di Torino
Bruno G; Bringhen S; Maffei I; Iannaccone A; Crea T; Ravera A; Astarita A; Vallelonga F; Salvini M; Gay F; Veglio F; Milan A;
Do we need cytogenetics in the follow-up of multiple myeloma? in British journal of haematology / Br J Haematol. 2019 May;185(3):399-401. doi: 10.1111/bjh.15781. Epub 2019 Feb 1.
2019
AOU Città della Salute di Torino
Gay F; Goldschmidt H;
Redefining the treatment paradigm for multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2019 Jun;20(6):743-744. doi: 10.1016/S1470-2045(19)30295-5. Epub 2019 May 13.
2019
AOU Città della Salute di Torino
Gay F; Mina R;
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. in Journal of internal medicine / J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.
2019
AOU Città della Salute di Torino
Boccadoro M; Dimopoulos MA; Caers J; Gramatzki M; Auner HW; Ludwig H; Driessen C; Cavo M; Goldschmidt H; Terpos E; Zweegman S; Offidani M; Larocca A; Gay F; Wäsch R; Ferri C; D'Agostino M; Milan A; Bringhen S; Einsele H; Sonneveld P; Engelhardt M;
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. in Cancers / Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.
2019
AOU Città della Salute di Torino
Bonello F; Mina R; Boccadoro M; Gay F;
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. in Cancers / Cancers (Basel). 2019 Dec 13;11(12):2015. doi: 10.3390/cancers11122015.
2019
AOU Città della Salute di Torino
D'Agostino M; Bertamini L; Oliva S; Boccadoro M; Gay F;
Moving Toward Continuous Therapy in Multiple Myeloma. in Clinical hematology international / Clin Hematol Int. 2019 Nov 12;1(4):189-200. doi: 10.2991/chi.d.191101.001. eCollection 2019 Dec.
2019
AOU Città della Salute di Torino
Bonello F; Cetani G; Bertamini L; Gay F; Larocca A;
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. in Cytometry. Part A : the journal of the International Society for Analytical Cytology / Cytometry A. 2019 Apr;95(4):416-418. doi: 10.1002/cyto.a.23752. Epub 2019 Mar 25.
2019
AOU Città della Salute di Torino
Castella B; Mina R; Gay F;
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. in Current medicinal chemistry / Curr Med Chem. 2019;26(32):5968-5981. doi: 10.2174/0929867325666180514114806.
2019
AOU Città della Salute di Torino
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F;
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). in Haematologica / Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26.
2018
AOU Città della Salute di Torino
Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M; Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; et alii...
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. in JAMA oncology / JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.
2018
AOU Città della Salute di Torino
Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; et alii...
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. in Haematologica / Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.
2018
AOU Città della Salute di Torino
Caers J; Garderet L; Kortüm KM; O'Dwyer ME; van de Donk NWCJ; Binder M; Dold SM; Gay F; Corre J; Beguin Y; Ludwig H; Larocca A; Driessen C; Dimopoulos MA; Boccadoro M; Gramatzki M; Zweegman S; Einsele H; Cavo M; Goldschmidt H; Sonneveld P; Delforge M; Auner HW; Terpos E; Engelhardt M; Caers J; Garderet L; Kortüm KM; O'Dwyer ME; et alii...
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21
2018
AO Cuneo
AOU Città della Salute di Torino
Fanti S; Ghedini P; Cavo M; Gamberi B; Gay F; Patriarca F; Gallamini A; Bellò M; Bertone E; Rensi M; Bianchi A; Chauvie S; Nanni C; Versari A; Zamagni E;
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? in Annals of hematology / Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27.
2018
AOU Città della Salute di Torino
Allcott K; Flament A; Gay F; Leleu X; Delforge M;
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension / High Blood Press Cardiovasc Prev. 2018 Jun;25(2):209-218. doi: 10.1007/s40292-018-0256-1. Epub 2018
2018
AOU Città della Salute di Torino
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A;
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2.
2018
AOU Città della Salute di Torino
Beksac M; Waage A; van de Donk NWCJ; Weisel K; Kaiser M; Jackson G; Goldschmidt H; Leleu X; Cook G; Mateos MV; Garderet L; Zweegman S; Terpos E; San-Miguel JF; Dimopoulos MA; Cavo M; Mohty M; Hajek R; Boccadoro M; Avet-Loiseau H; Moreau P; Gay F; Einsele H; Facon T; Delforge M; Ludwig H; Mellqvist UH; Engelhardt M; Caers J; et alii...
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. in Journal of cancer research and clinical oncology / J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19
2018
AOU Città della Salute di Torino
AOU Novara
Gay F; Petrucci MT; Boccadoro M; Offidani M; Palumbo A; Corradini P; Musto P; Tacchetti P; Nagler A; Benevolo G; Ria R; Caravita T; Cangialosi C; Marcatti M; Ponticelli E; Baldini L; Rocco S; Cascavilla N; Rizzi R; Angelucci E; Nozzoli C; Oddolo D; Ben-Yehuda D; Guglielmelli T; Mina R; Crippa C; Patriarca F; Spada S; De Paoli L; et alii...
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. in Haematologica / Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7.
2018
AOU Città della Salute di Torino
Cavo M; Kröger N; Boccadoro M; Dimopoulos M; Einsele H; Ludwig H; Straka C; Hajek R; Garderet L; Zamagni E; Oliva S; van de Donk N; Gramatzki M; Caers J; Auner HW; Giaccone L; Wäsch R; Terpos E; Engelhardt M; Gay F; Goldschmidt H; Bruno B; Sonneveld P;
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14.
2018
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara
Gay F; Nagler A; Boccadoro M; Montefusco V; Palumbo A; Ribolla R; Siniscalchi A; Patriarca F; Pezzatti S; De Sabbata G; Di Renzo N; Rizzi R; Gamberi B; Baldini L; Guglielmelli T; Gilestro M; Catalano L; Marcatti M; Spada S; Petrucci MT; Ria R; Offidani M; De Paoli L; Conticello C; D'Agostino M;
CD38 as an immunotherapeutic target in multiple myeloma. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. Epub 2018 Nov
2018
AOU Città della Salute di Torino
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F; Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F;
Special problems in the management of elderly patients with multiple myeloma. in European journal of internal medicine / Eur J Intern Med. 2018 Dec;58:64-69. doi: 10.1016/j.ejim.2018.05.027.
2018
AOU Città della Salute di Torino
Gay F; Larocca A; Gay F; Larocca A;
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25.
2018
AOU Città della Salute di Torino
Einsele H; Boccadoro M; Dimopoulos MA; Offidani M; Gramatzki M; Auner HW; Caers J; Bringhen S; Ludwig H; Straka C; Cavo M; Gay F; Goldschmidt H; Scheubeck S; D'Agostino M; Wäsch R; Terpos E; Zweegman S; Dold SM; Larocca A; Sonneveld P; Engelhardt M; Larocca A; Dold SM; Zweegman S; Terpos E; Wäsch R; D'Agostino M; Scheubeck S; et alii...
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. in Frontiers in immunology / Front Immunol. 2018 Nov 27;9:2749. doi: 10.3389/fimmu.2018.02749. eCollection 2018.
2018
AOU Città della Salute di Torino
Gay F; Boccadoro M; D'Agostino M; Troia R; Oliva S; Oliva S; Troia R; D'Agostino M; Boccadoro M; Gay F;
Emerging drugs and combinations to treat multiple myeloma. in Oncotarget / Oncotarget. 2017 Jul 15;8(36):60656-60672. doi: 10.18632/oncotarget.19269. eCollection 2017 Sep 1.
2017
AOU Città della Salute di Torino
Larocca A; Mina R; Gay F; Bringhen S; Boccadoro M;
Autologous transplant for myeloma: when the old meets the new. in Oncotarget / Oncotarget. 2017 Oct 8;8(53):90618-90619. doi: 10.18632/oncotarget.21605. eCollection 2017 Oct 31.
2017
AOU Città della Salute di Torino
Gay F; Genuardi M; Boccadoro M;
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. in European journal of haematology / Eur J Haematol. 2017 Mar;98(3):289-295. doi: 10.1111/ejh.12834. Epub 2017 Jan 5.
2017
AOU Città della Salute di Torino
Offidani M; Corvatta L; Bringhen S; Gentili S; Troia R; Maracci L; Larocca A; Gay F; Leoni P; Boccadoro M;
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. in American journal of hematology / Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.
2017
AOU Città della Salute di Torino
Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F;
Novel investigational drugs active as single agents in multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 Ma
2017
AOU Città della Salute di Torino
D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F;
Multiple myeloma. in Nature reviews. Disease primers / Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46.
2017
AOU Città della Salute di Torino
Kumar SK; Rajkumar V; Kyle RA; van Duin M; Sonneveld P; Mateos MV; Gay F; Anderson KC;
Plasma cell leukemia: update on biology and therapy. in Leukemia & lymphoma / Leuk Lymphoma. 2017 Jul;58(7):1538-1547. doi: 10.1080/10428194.2016.1250263. Epub 2016 Nov 6.
2017
AOU Città della Salute di Torino
Palumbo A; Gay F; Cerrato C; D'Agostino M; Mina R;
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. in Oncotarget / Oncotarget. 2017 Jan 24;8(4):5924-5935. doi: 10.18632/oncotarget.12641.
2017
AOU Città della Salute di Torino
Caravita T; Conticello C; Liberati AM; Pescosta N; Petrucci MT; Saraci E; Patriarca F; Genuardi M; Bernardini A; Pautasso C; Passera R; Ferrero S; Drandi D; Gay F; Muccio VE; Gilestro M; Gambella M; Oliva S; Rocci A; Musto P; Boccadoro M; Palumbo A; Omedè P;
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. in Leukemia / Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353.
2017
AOU Città della Salute di Torino
Ludwig H; Delforge M; Facon T; Einsele H; Gay F; Moreau P; Avet-Loiseau H; Boccadoro M; Hajek R; Mohty M; Cavo M; Dimopoulos MA; San-Miguel JF; Terpos E; Zweegman S; Garderet L; Mateos MV; Cook G; Leleu X; Goldschmidt H; Jackson G; Kaiser M; Weisel K; van de Donk NWCJ; Waage A; Beksac M; Mellqvist UH; Engelhardt M; Caers J; et alii...
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):471-478. doi: 10.1016/j.clml.2017.06.014. Epub 2017 Jun 1
2017
AOU Città della Salute di Torino
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B; Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B;
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. in Leukemia / Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23.
2017
AOU Città della Salute di Torino
Nagler A; Patriarca F; Caravita T; Falcone AP; Malfitano A; Cafro AM; Liberati AM; Troia R; Omedé P; Offidani M; Carella AM; Salvini M; Ria R; Campbell P; Spada S; Evangelista A; Catalano L; Musto P; Conticello C; Montefusco V; Petrucci MT; Oliva S; Gay F; Spencer A; Hajek R; Palumbo A; Boccadoro M;
Stem Cell Transplantation in Multiple Myeloma. in Current cancer drug targets / Curr Cancer Drug Targets. 2017;17(9):769-781. doi: 10.2174/1568009616666160920090236.
2017
AOU Città della Salute di Torino
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A;
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.
2016
AO Cuneo
AOU Città della Salute di Torino
Fanti S; Gamberi B; Cavo M; Gay F; Patriarca F; Gallamini A; Rambaldi I; Rensi M; Bellò M; Bianchi A; Versari A; Chauvie S; Zamagni E; Nanni C;
Nuances in the Management of Older People With Multiple Myeloma. in Current hematologic malignancy reports / Curr Hematol Malig Rep. 2016 Jun;11(3):241-51. doi: 10.1007/s11899-016-0323-4.
2016
AOU Città della Salute di Torino
Pawlyn C; Gay F; Larocca A; Roy V; Ailawadhi S;
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
2015
AOU Città della Salute di Torino
Palumbo A; Gay F; Cavallo F; Di Raimondo F; Larocca A; Hardan I; Nagler A; Petrucci MT; Hajek R; Pezzatti S; Delforge M; Patriarca F; Donato F; Cerrato C; Nozzoli C; Yu Z; Boccadifuoco L; Caravita T; Benevolo G; Guglielmelli T; Vincelli D; Jacques C; Dimopoulos MA; Ciccone G; Musto P; Corradini P; Cavo M; Boccadoro M;
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2015 Oct;21(10):1705-6. doi: 10.1016/j.bbmt.2015.08.005. Epub 2015 Aug
2015
AOU Città della Salute di Torino
Gay F; Palumbo A;
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
2015
AOU Città della Salute di Torino
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A;
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. in Stem cell research & therapy / Stem Cell Res Ther. 2015 Apr 17;6(1):64. doi: 10.1186/s13287-015-0033-1.
2015
AOU Città della Salute di Torino
Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M;
Autologous transplantation and maintenance therapy in multiple myeloma. in The New England journal of medicine / N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.
2014
AOU Città della Salute di Torino
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M;
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2014 Sep;23(9):1193-209. doi: 10.1517/13543784.2014.920821. Epub 2014 Ju
2014
AOU Città della Salute di Torino
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A;
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. in Haematologica / Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. Epub 2014 Jul 11.
2014
AOU Città della Salute di Torino
Caltagirone S; Ruggeri M; Aschero S; Gilestro M; Oddolo D; Gay F; Bringhen S; Musolino C; Baldini L; Musto P; Petrucci MT; Gaidano G; Passera R; Bruno B; Palumbo A; Boccadoro M; Omedè P;
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. in British journal of haematology / Br J Haematol. 2014 Mar;164(6):841-50. doi: 10.1111/bjh.12719. Epub 2014 Jan 23.
2014
AOU Città della Salute di Torino
Rocci A; Gambella M; Aschero S; Baldi I; Trusolino L; Cavallo F; Gay F; Larocca A; Magarotto V; Omedè P; Isaia G; Bertotti A; Liberati AM; Catalano L; De Rosa L; Musto P; Vallone R; Falcone A; Drandi D; Ladetto M; Comoglio PM; Boccadoro M; Palumbo A;
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. in Haematologica / Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21.
2014
AOU Città della Salute di Torino
van de Donk NW; Palumbo A; Johnsen HE; Engelhardt M; Gay F; Gregersen H; Hajek R; Kleber M; Ludwig H; Morgan G; Musto P; Plesner T; Sezer O; Terpos E; Waage A; Zweegman S; Einsele H; Sonneveld P; Lokhorst HM;
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2014 Aug;14(8):1127-44. doi: 10.1517/14712598.2014.908848. Epub 2014 Apr 21.
2014
AOU Città della Salute di Torino
Donato F; Gay F; Bringhen S; Troia R; Palumbo A;
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report. in Transplant infectious disease : an official journal of the Transplantation Society / Transpl Infect Dis. 2014 Aug;16(4):653-7. doi: 10.1111/tid.12245. Epub 2014 Jun 11.
2014
AOU Città della Salute di Torino
Festuccia M; Giaccone L; Gay F; Brunello L; Maffini E; Ferrando F; Talamo E; Boccadoro M; Serra R; Barbui A; Bruno B;
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. in Expert opinion on drug metabolism & toxicology / Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1517-27. doi: 10.1517/17425255.2013.827169. Epub 2013
2013
AOU Città della Salute di Torino
Gay F; Mina R; Troia R; Bringhen S;
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. in Blood / Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17.
2013
AOU Città della Salute di Torino
Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A;